EMA Opinion under re-examination: KemSu (ketamine hydrochloride;sufentanil citrate) — Proveca Pharma Limited

View source ↗

Summary

EMA Opinion under re-examination for KemSu (ketamine hydrochloride; sufentanil citrate) by Proveca Pharma Limited in the acute pain therapeutic area.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pain

Drugs mentioned

• KemSu (ketamine hydrochloride; sufentanil citrate)

Snippet

Status: Opinion under re-examination. Therapeutic area: Acute Pain. MAH: Proveca Pharma Limited. Decision date: 23/07/2026